Neurocrine Biosciences | NBIX - Passività Correnti





Passività Correnti Cambiamento Data
AbbVie USD 43.29B 3.9B 2025-12
Acadia Pharmaceuticals USD 277.11M 79.47M 2025-12
Agios Pharmaceuticals USD 82.21M 7.45M 2025-12
ALKERMES USD 543.44M 69.08M 2025-12
Alnylam Pharmaceuticals USD 1.47B 89.13M 2025-12
Amgen USD 25.49B 3.7B 2025-12
Biogen USD 3.35B 59.4M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Cytokinetics USD 202.45M 60.31M 2025-12
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Exelixis USD 405.64M 31.86M 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
Halozyme Therapeutics USD 177.09M 660.14M 2025-12
Incyte USD 1.52B 176.44M 2025-12
Ionis Pharmaceuticals USD 783M 120.46M 2025-12
Nektar Therapeutics USD 66.34M 5.05M 2025-09
Neurocrine Biosciences USD 743.4M 105.4M 2025-12
Pfizer USD 36.6B 1.13B 2025-09
Prothena USD 51.44M 16.37M 2025-09
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Repligen USD 135.83M 4.69M 2025-12
Rigel Pharmaceuticals USD 94.4M 7.76M 2025-09
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
Teva Pharmaceutical Industries USD 13.46B 1.96B 2025-12
Ultragenyx Pharmaceutical USD 340.02M 46.78M 2025-09
Vertex Pharmaceuticals USD 3.86B 614.1M 2025-12
Xoma USD 28.3M 6.81M 2025-09